Aethlon

US-based therapeutic devices developer Aethlon Medical has announced that its Hemopurifier device has been named as one of the 25 best inventions of 2014 by Time Magazine.

The first-class bio-filtration device Hemopurifier eliminates viruses and immunosuppressive proteins from the circulatory system of infected individuals.

Hemopurifier targets the rapid elimination of circulating viruses and tumour-secreted exosomes that promote cancer progression.

The device was used in the treatment of Ebola, human immunodeficiency virus (HIV) and Hepatitis C.

The Hemopurifier therapy was recently successful in treating an Ebola patient with multiple organ failure.

“Hemopurifier targets the rapid elimination of circulating viruses and tumour-secreted exosomes that promote cancer progression.”

In September, the company received independent internal review board (IRB) approval to initiate human clinical trials of Hemopurifier therapy at DaVita Med Center Dialysis in Houston, Texas, US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The US Food and Drug Administration (FDA) previously approved an investigational device exemption (IDE), allowing the start of Hemopurifier feasibility studies in the US.

As a result of the independent IRB approval, the company is now permitted to start the IDE approved trial.

Patients who meet the inclusion / exclusion criteria of the trial are expected to be enrolled in the next few weeks.


Image: Aethlon Hemopurifier. Photo: courtesy of Aethlon Medical Inc.